<DOC>
	<DOC>NCT01134835</DOC>
	<brief_summary>To test the hypothesis that stimulation of PPAR-γ receptors has a therapeutic role in the treatment of asthma.</brief_summary>
	<brief_title>PPAR-gamma: a Novel Therapeutic Target for Asthma?</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Age 1875 of either sex with a clinical diagnosis of asthma, FEV1 ≥ 60% predicted and an increase in FEV1 of greater than 12% following inhaled salbutamol 400μg or Peak Expiratory Flow (PEF) variability &gt;12% during runin. Allowed medication: 0800μg inhaled beclomethasone diproprionate or equivalent and as required short acting beta agonist. Current smoking, &gt; 10 pack years smoking history, Treatment with leukotriene antagonists, Liver or cardiovascular disease, Oral steroid treatment or exacerbation within 6 weeks, Females who are pregnant, lactating or not using adequate contraception, Any contraindication to pioglitazone (hypersensitivity to pioglitazone, cardiac failure, history of cardiac failure, hepatic impairment, diabetic ketoacidosis), Oral or insulin treatment for diabetes, Treatment with gemfibrozil or rifampicin.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>